Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple Myeloma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the clinical pharmacokinetic and pharmacodynamic
profiles of the 2 doses of VELCADE (bortezomib) for Injection. Patients who volunteer to
participate in the pharmacogenetic portion of the study, an additional blood sample will be
collected before the Cycle 1 Day 1 dose of bortezomib to assess the genotype of drug
metabolizing enzymes.